News | September 10, 2024
Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Agreement further expands Aptar Pharma’s leading respiratory portfolio
The recent inspection covered both cGMP and PAI processes
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Konieczny has served as Interim CEO since April 2024
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Subscribe To Our Newsletter & Stay Updated
